HRP20030631A2 - An improved process for preparing pure ondansetron hydrocloride dihydrate - Google Patents

An improved process for preparing pure ondansetron hydrocloride dihydrate Download PDF

Info

Publication number
HRP20030631A2
HRP20030631A2 HR20030631A HRP20030631A HRP20030631A2 HR P20030631 A2 HRP20030631 A2 HR P20030631A2 HR 20030631 A HR20030631 A HR 20030631A HR P20030631 A HRP20030631 A HR P20030631A HR P20030631 A2 HRP20030631 A2 HR P20030631A2
Authority
HR
Croatia
Prior art keywords
solution
ondansetron
methyl
hydrochloride dihydrate
carbazolone
Prior art date
Application number
HR20030631A
Other languages
English (en)
Croatian (hr)
Inventor
Bachar Eliezer
Lidor-Hadas Ramy
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20030631A2 publication Critical patent/HRP20030631A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20030631A 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrocloride dihydrate HRP20030631A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
PCT/US2002/000853 WO2002055492A2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Publications (1)

Publication Number Publication Date
HRP20030631A2 true HRP20030631A2 (en) 2005-06-30

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030631A HRP20030631A2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrocloride dihydrate

Country Status (21)

Country Link
EP (1) EP1355881A4 (cs)
JP (1) JP2004526692A (cs)
KR (3) KR20070054749A (cs)
CN (2) CN1496350A (cs)
AU (1) AU2002236753B2 (cs)
CA (1) CA2433720A1 (cs)
CZ (1) CZ20032090A3 (cs)
DE (1) DE02703115T1 (cs)
ES (1) ES2219201T1 (cs)
HR (1) HRP20030631A2 (cs)
HU (1) HUP0400767A2 (cs)
IL (1) IL156835A0 (cs)
IS (1) IS6869A (cs)
MX (1) MXPA03006215A (cs)
NO (1) NO20033147L (cs)
PL (1) PL368837A1 (cs)
SK (1) SK9892003A3 (cs)
TR (1) TR200401460T3 (cs)
WO (1) WO2002055492A2 (cs)
YU (1) YU56103A (cs)
ZA (1) ZA200305338B (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483566A1 (en) 2002-04-29 2003-11-13 Biogal Gyogyszergyar Rt. Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
WO2006046253A1 (en) * 2004-10-26 2006-05-04 Ipca Laboratories Limited A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
SK6182003A3 (en) * 2000-10-30 2004-03-02 Teva Pharma Crystalline and solvated forms of ondansetrone hydrochloride and preparation thereof

Also Published As

Publication number Publication date
YU56103A (sh) 2006-05-25
WO2002055492A3 (en) 2003-02-13
ZA200305338B (en) 2004-07-12
EP1355881A2 (en) 2003-10-29
ES2219201T1 (es) 2004-12-01
IS6869A (is) 2003-07-08
AU2002236753B2 (en) 2007-06-28
TR200401460T3 (cs) 2004-08-23
EP1355881A4 (en) 2004-03-31
HUP0400767A2 (hu) 2004-07-28
CN101045704A (zh) 2007-10-03
SK9892003A3 (en) 2004-05-04
CN1496350A (zh) 2004-05-12
KR20030068583A (ko) 2003-08-21
KR20070054749A (ko) 2007-05-29
CA2433720A1 (en) 2002-07-18
JP2004526692A (ja) 2004-09-02
IL156835A0 (en) 2004-02-08
PL368837A1 (en) 2005-04-04
CZ20032090A3 (cs) 2004-08-18
KR20060113792A (ko) 2006-11-02
WO2002055492A2 (en) 2002-07-18
NO20033147L (no) 2003-09-02
MXPA03006215A (es) 2005-02-17
NO20033147D0 (no) 2003-07-09
DE02703115T1 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
RS56103B1 (sr) Ublažavanje uticaja interferencije na uplink strani prilagođenjem snage predaje ćelije sa otvorenim pristupom
JPS62114987A (ja) 新規４―ベンジル―１―（２ｈ）―フタラジノン―誘導体及びその製法
EA021440B1 (ru) Способ производства фармацевтически активного вещества
RS61506B1 (sr) Kompozicije fenfluramina i postupci za njihovu pripremu
SK8872002A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
EP1451188A1 (fr) Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo 3.2.2]-nonane, leur preparation et leur application en therapeutique
WO2005075474A1 (ja) コハク酸ソリフェナシン含有組成物
JP2004530638A (ja) 結晶性ベンラファクシン塩基、及び新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法
JP2005507900A (ja) シタロプラムの製造方法
HRP20030631A2 (en) An improved process for preparing pure ondansetron hydrocloride dihydrate
CN108358900A (zh) 一种阿法替尼及其马来酸盐的制备方法
TWI291956B (en) Improved process
WO2007088558A2 (en) A process for purification of valsartan
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate
CN117769547A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法
CN113979875A (zh) 一种地佐辛衍生物晶型a及其制备方法和应用
CN114671829B (zh) 以茚酮和二苯并氮杂卓为母核的杂二联体及其盐酸盐、其制备方法和用途
US20100256208A1 (en) Novel process
CN110885315A (zh) 左西孟旦药重要中间体的制备方法
WO2020016827A1 (en) Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
CN103857679A (zh) 制备5-[2-[7-(三氟甲基)-5-[4-(三氟甲基)苯基]吡唑并[1，5-a]嘧啶-3-基]乙炔基]-2-吡啶胺的方法
CN107628983B (zh) 高手性纯度的阿普斯特
CN115611864A (zh) 一种昂丹司琼类化合物及其制备方法与应用
CN118496158A (zh) 一种艾曲泊帕乙醇胺的制备方法

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061230

Year of fee payment: 6

ODBI Application refused